Cargando…

Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express the Sodium Iodide Symporter in Patients with Recurrent or Refractory Multiple Myeloma

MV-NIS is an Edmonston-lineage oncolytic measles virus expressing the human sodium-iodide symporter--a means for monitoring by noninvasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dispenzieri, Angela, Tong, Caili, LaPlant, Betsy, Lacy, Martha Q., Laumann, Kristina, Dingli, David, Zhou, Yumei, Federspiel, Mark J., Gertz, Morie A., Hayman, Suzanne, Buadi, Francis, O’Connor, Michael, Lowe, Val J., Peng, Kah-Whye, Russell, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656536/ https://www.ncbi.nlm.nih.gov/pubmed/28439108 http://dx.doi.org/10.1038/leu.2017.120

Ejemplares similares

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus
por: Liu, Yu-Ping, et al.
Publicado: (2011)

Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy
por: Kumar, Shaji K., et al.
Publicado: (2013)

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
por: Li, H, et al.
Publicado: (2010)

Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019)

Improved Noninvasive In Vivo Tracking of AAV-9 Gene Therapy Using the Perchlorate-Resistant Sodium Iodide Symporter from Minke Whale
por: Concilio, Susanna C., et al.
Publicado: (2021)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Measles Edmonston Vaccine Strain Derivatives have Potent Oncolytic Activity against Osteosarcoma
por: Musibay, Evidio Domingo, et al.
Publicado: (2014)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation
por: Chakraborty, Rajshekhar, et al.
Publicado: (2017)

Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
por: Hutzen, Brian, et al.
Publicado: (2012)

Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020)

Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023)

Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
por: Pang, Li, et al.
Publicado: (2021)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma
por: Zhang, Shu-Cheng, et al.
Publicado: (2012)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Determination Factors Associated with Immune Responses Towards First Dose Edmonston-Zagreb (EZ) Measles Vaccine in Indonesian Infants
por: Teni Nurlatifah, HR, et al.
Publicado: (2021)

Tumor microenvironment affects exogenous sodium/iodide symporter expression
por: Castillo-Rivera, Fabio, et al.
Publicado: (2020)

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
por: Packiriswamy, Nandakumar, et al.
Publicado: (2020)

Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter
por: Read, Martin L., et al.
Publicado: (2022)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

Decreased Expression of Thyroglobulin and Sodium Iodide Symporter Genes in Hashimoto's Thyroiditis
por: Popławska-Kita, Anna, et al.
Publicado: (2014)

Physiological sodium concentrations enhance the iodide affinity of the Na(+)/I(−) symporter
por: Nicola, Juan P., et al.
Publicado: (2014)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
por: Chakraborty, R, et al.
Publicado: (2016)

Conserved charged amino acid residues in the extracellular region of sodium/iodide symporter are critical for iodide transport activity
por: Li, Chia-Cheng, et al.
Publicado: (2010)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies
por: Penheiter, Alan R, et al.
Publicado: (2012)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
por: Al Saleh, Abdullah S., et al.
Publicado: (2022)

Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer
por: Micali, Salvatore, et al.
Publicado: (2014)

In Vivo Myoblasts Tracking Using the Sodium Iodide Symporter Gene Expression in Dogs
por: Punzón, Isabel, et al.
Publicado: (2020)

CRISPR/Cas9‐mediated introduction of the sodium/iodide symporter gene enables noninvasive in vivo tracking of induced pluripotent stem cell‐derived cardiomyocytes
por: Ostrominski, John W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0bg7q8r5541gdrm1bi48ldefg7